PMS-ROPINIROLE TABLET
Land: Kanada
Tungumál: enska
Heimild: Health Canada
Vara einkenni
(SPC)
21-06-2017
Sum skjöl fyrir þessa vöru eru ekki tiltæk eins og er, þú getur sent beiðni til þjónustu við viðskiptavini okkar og við munum láta þig vita um leið og við getum fengið þau.
Senda beiðni.
Senda beiðni.
Virkt innihaldsefni:
ROPINIROLE (ROPINIROLE HYDROCHLORIDE)
Fáanlegur frá:
PHARMASCIENCE INC
ATC númer:
N04BC04
INN (Alþjóðlegt nafn):
ROPINIROLE
Skammtar:
2MG
Lyfjaform:
TABLET
Samsetning:
ROPINIROLE (ROPINIROLE HYDROCHLORIDE) 2MG
Stjórnsýsluleið:
ORAL
Einingar í pakka:
10/100
Gerð lyfseðils:
Prescription
Lækningarsvæði:
NONERGOT-DERIVATIVE DOPAMINE RECEPTOR AGONISTS
Vörulýsing:
Active ingredient group (AIG) number: 0132618004; AHFS:
Leyfisstaða:
APPROVED
Leyfisdagur:
2009-07-22
Vara einkenni
PRODUCT MONOGRAPH
PR
PMS-ROPINIROLE
Ropinirole Hydrochloride Tablets, House
0.25 mg, 0.5 mg 1.0 mg, 2.0 mg, 5.0 mg ropinirole
(as ropinirole hydrochloride)
ANTIPARKINSONIAN AGENT / DOPAMINE AGONIST
PHARMASCIENCE INC.
DATE OF REVISION:
6111 Ave. Royalmount, Suite 100
June 12, 2017
Montreal, Quebec
H4P 2T4
www.pharmascience.com
SUBMISSION CONTROL NO: 206310
_pms-ROPINIROLE Product Monograph Page 2 of 52 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
........................................................................
3
INDICATIONS AND CLINICAL USE
..............................................................................
4
CONTRAINDICATIONS
...................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................
5
ADVERSE REACTIONS
.................................................................................................
10
DRUG INTERACTIONS
..................................................................................................
21
DOSAGE AND ADMINISTRATION
..............................................................................
23
OVERDOSAGE
................................................................................................................
24
ACTION AND CLINICAL PHARMACOLOGY
............................................................ 25
STORAGE AND STABILITY
.........................................................................................
28
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................. 28
PART II: SCIENTIFIC INFORMATION
................................................................................
30
PHARMACEUTICAL INFORMATION
.........................................................................
30
CLINICAL TRIALS
......................................................................
Lestu allt skjalið
